IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study

Croca, Sara; Bassett, Paul; Chambers, S; Davari, Maria; Alber, Karim Fouad; Leach, Oliver; Ioannou, Yiannis; Giles, Ian; Isenberg, David; Rahman, Anisur

doi:10.1186/s13075-015-0539-z

Cited by 26 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, sample size may play a role since this is the first large-scale study of anti-apoA-1 IgG in the community. Furthermore, as only baseline anti-apoA-1 IgG levels were measured, we could not assess potential variations of anti-ApoA-1 IgG levels over time (38) and especially after cardiovascular events, a point that will need to be determined in future studies.…”

Section: Prevalence Of Anti-apoa-1 Igg In the General Populationmentioning

confidence: 99%

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

Antiochos¹,

Marques‐Vidal²,

Virzi³

et al. 2016

Thromb Haemost

View full text Add to dashboard Cite

We aimed to determine the association between autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of CV risk in the general population. Cross-sectional data were obtained from 6649 subjects (age 52.6 ± 10.7 years, 47.4 % male) of the population-based CoLaus study. CVD was defined as myocardial infarction, angina pectoris, percutaneous revascularisation or bypass grafting for ischaemic heart disease stroke or transient ischaemic attack, and was assessed according to standardised medical records. Anti-apoA-1 IgG and biological markers were measured by ELISA and conventional automated techniques, respectively. Prevalence of high anti-apoA-1 IgG levels in the general population was 19.9 %. Presence of anti-apoA-1 IgG was significantly associated with CVD [odds ratio 1.34, 95 % confidence interval (1.05-1.70), p=0.018], independently of established CV risk factors (CVRFs) including age, sex, hypertension, smoking, diabetes, low and high-density lipoprotein cholesterol levels. The n=455 (6.8 %) study participants with a history of CVD (secondary prevention subgroup) presented higher median anti-ApoA-1 IgG values compared with subjects without CVD (p=0.029). Among patients in the secondary prevention subgroup, those with positive anti-apoA-1 IgG levels had lower HDL (p=0.002) and magnesium (p=0.001) levels, but increased uric acid and high-sensitivity C-reactive protein levels (p=0.022, and p<0.001, respectively) compared to patients with negative anti-apoA-1 IgG levels. In conclusion, anti-apoA-1 IgG levels are independently associated with CVD in the general population and also related to CV biomarkers in secondary prevention. These findings indicate that anti-apoA-1 IgG may represent a novel CVRF and need further study in prospective cohorts.

show abstract

Section: Prevalence Of Anti-apoa-1 Igg In the General Populationmentioning

confidence: 99%

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

Antiochos¹,

Marques‐Vidal²,

Virzi³

et al. 2016

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…Among other autoantibodies of possible cardiovascular relevance, we and others focused our interest on antibodies to apolipoprotein A-1 (apoA-1), the major protein fraction of high-density lipoprotein (HDL). High levels of anti-apoA-1 IgG have been initially described in patients with prothrombotic autoimmune diseases associated with an increased CV risk such as systemic lupus erythematosus (13)(14)(15), and primary anti-phospholipid syndrome (16). Later on, these autoantibodies were found to be elevated in high CV risk settings, such as acute coronary syndromes (17)(18)(19)(20), severe carotid stenosis (21,22), end-stage renal disease (23), and rheumatoid arthritis patients (24,25).…”

Section: Introductionmentioning

confidence: 99%

Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis

Pagano

Carbone²,

Burger³

et al. 2016

Thromb Haemost

View full text Add to dashboard Cite

SummaryHumoral autoimmune-mediated inflammation plays a role in atherogenesis, and potentially in arterial thrombosis. Anti-apolipoprotein A-1 (apoA-1) IgG have been reported to represent emergent mediators of atherogenesis through Toll-like receptors (TLR) 2, 4 and CD14 signalling. We investigated the role of anti-apoA-1 IgG on tissue factor (TF) expression and activation, a key coagulation regulator underlying atherothrombosis. Atherothrombosis features were determined by immunohistochemical TF staining of human carotid biopsies derived from patients with severe carotid stenosis undergoing elective surgery (n=176), and on aortic roots of different genetic backgrounds mice (ApoE -/-; TLR2 -/-ApoE -/-and TLR4 -/-ApoE -/-) exposed to passive immunisation with anti-apoA-1 IgG. Human serum levels of anti-apoA-1 IgG were measured by ELISA. In vitro, on human-monocyte-derived-macrophages (HMDM) the anti-apoA-1 IgG increased TF expression and activity were analysed by FACS and chromogenic assays in presence of different pharmacological inhibitors. Human serum anti-apoA-1 IgG levels significantly correlated to intraplaque TF expression in carotid biopsies (r=0.31, p<0.001), which was predictive of clinically symptomatic lesions. On HMDM, anti-apoA-1 IgG induced a TLR2, 4/CD14-dependent increase in TF expression and activity, involving NF-kappaB and a c-Jun N-terminal kinase-dependent AP-1 transcription factors. In ApoE -/-mice, anti-apoA-1 IgG passive immunisation significantly enhanced intraplaque TF expression when compared to control IgG. This effect was lost in both TLR2 -/-ApoE -/-and TLR4 -/-ApoE -/-backgrounds. These results demonstrate that anti-apoA-1 IgG are associated with TF expression in human atherosclerotic plaques, induce TF expression in vitro and in vivo through TLR2 and 4 signalling, supporting a possible causal relationship between anti-apoA-1 IgG and atherothrombosis.

show abstract

“…It was recently proposed that apo‐A1 prevents autoimmunity and suppresses inflammation independently of cholesterol transport . Indeed, several studies showed that the levels of anti‐apo‐A1 and anti‐HDL antibodies were significantly higher in patients with systemic lupus erythematosus (SLE) and other systemic autoimmune disorders, and were positively associated with disease activity. Thus, another possible explanation for current results is that lower HDL‐C may represent more severe underlying disease and consequently a higher risk of osteonecrosis.…”

Section: Discussionmentioning

confidence: 99%

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Wang

Hua

Chang

et al. 2019

Journal Orthopaedic Research

View full text Add to dashboard Cite

Early diagnosis and prevention of glucocorticoid (GC)‐induced osteonecrosis of the femoral head (ONFH) continues to be a challenging problem for clinicians and researchers. However, the role of circulating biomarkers for GC‐induced ONFH, which may reveal individual susceptibility and facilitate earlier diagnosis, remains to be determined. The aim of this study was to identify potential biomarkers that may predict early GC‐induced ONFH. A total of 123 patients scheduled for initial systemic GC therapy were enrolled in this prospective nested case–control study. The serum concentrations of 13 potential biomarkers were measured in seven patients with GC‐induced ONFH, diagnosed instantly after short‐term use of GCs and in 20 controls who did not develop osteonecrosis despite similar GC therapy. Biomarkers were measured both before and after taking GCs to identify any differences in marker levels and the changes during GC therapy between two groups. Type I collagen cross‐linked C‐telopeptide (β‐CTX; p = 0.000) was significantly lower, high‐density lipoprotein cholesterol (p = 0.092) and apolipoprotein (apo)‐B/apo‐A1 (p = 0.085) tended to be lower and higher, respectively, before GC treatment in osteonecrosis group. After GC therapy, β‐CTX (p = 0.014) was significantly lower and amino terminal telopeptide of procollagen type I (PINP; p = 0.068) tended to be lower in the osteonecrosis group. As secondary outcomes, we observed remarkable changes in nine potential biomarkers following short‐term GC therapy in both groups. In conclusion, we found that β‐CTX, could potentially be used to predict GC‐induced ONFH before GC therapy. Lower β‐CTX and PINP are promising biomarkers for the early diagnosis of GC‐induced ONFH. These findings need to be confirmed in large‐scale prospective studies. © 2019 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 37:2348–2357, 2019

show abstract

IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study

Cited by 26 publications

References 33 publications

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

Association between anti-apolipoprotein A-1 antibodies and cardiovascular disease in the general population

Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis

Serum Biomarkers Related to Glucocorticoid‐Induced Osteonecrosis of the Femoral Head: A Prospective Nested Case‐Control Study

Contact Info

Product

Resources

About